CNS-Penetrant Compound Library

Cat.No.L4700

A unique collection of 808 CNS-Penetrant compounds with biological activity for neurologic research.

Customize Your Library:

Cited by 324 Publications

Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

• A unique collection of 808 small molecule compounds with biological activity used for neurologic research and associated assays

•Targets 5-HT Receptor, DHFR, COX, RAAS, AChR, etc

• Some compounds have been approved by the FDA

• Structurally diverse, medicinally active, and cell permeable

• Rich documentation with structure, IC50, and customer reviews

• NMR and HPLC validated to ensure the highest purity

Formulation	737 compounds pre-dissolved in 10mM DMSO, 44 compounds pre-dissolved in 10mM water, 24 compounds pre-dissolved in 2mM DMSO and 3 compounds pre-dissolved in 2mM water
Container	96 Deep Well Plate Sealed With Aluminum Foil
Stability	12 months	-20°C	in DMSO
Stability	24 months	-80°C	in DMSO
Shipping	Blue ice or dry ice

Application of GPCR Compound Library in liver cancer (This article was published in Nature (IF=43) and took about 15 months):

Nature.2019;574(7777):268-272
Application of Kinase Inhibitor Library in colorectal cancer (This article was published in Nature Communications (IF=11) and took about 8 months):

Nat Commun. 2019 16;10(1):2197
Application of FDA-approved Drug Library in antivirus (This article was published in Cell Research (IF=17) and took about 13 months):

Cell Res. 2019;29(9):739-753
Application of FDA-approved Drug Library in metabolism (This article was published in Movement Disorders (IF=8) and took about 10 months):

Mov Disord. 2019;34(3):323-334
Application of Epigenetics Compound Library in acute lymphoblastic leukemia (This article was published in Blood (IF=16) and took about 16 months):

Blood. 2019 17;134(16):1323-1336
Application of Inhibitor Library in tumor immunology (This article was published in Cancer Immunol Res (IF=8.6) and took about 12 months):

Cancer Immunol Res.2017;5(9):790-803